doc. RNDr. Ondřej Slabý, Ph.D.

2017

• CAPOOR, M N; RUZICKA, F; SCMITZ, J E; JAMES, GA; MACHACKOVA, T; JANCALEK, R; SMRCKA, M; LIPINA, R; AHMED F S; ALAMIN, T; ANAND, N; BAIRD, J C; BHATIA, N; DEMIR-DEVIREN, S; EASTLACK, R.K.; FISHER, S; GARFIN, S R; GOGIA J S; GOKASLAN Z L; KUO C C, LEE Y, MAVROMMATIS K, MICHU E, NOSKOVA H, RAZ A, SANA J, SHAMIE A N, STEWART P S, STONEMETZ J L, WANG J C, WITHAM T F; COSCIA M F, BIRKENMAIER CH; FISCHETTI V A; SLABY, O., 2017:Propionibacterium acnes biofilm is present in intervertebral discs of patients undergoing microdiscectomy. PLoS One 4 (12)
• FEDORKO, M; JURACEK, J; STANIK, M; SVOBODA, M; POPRACH, A; BUCHLER, T; PACIKL, D; DOLEZEL, J; SLABY, O, 2017:Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. BIOCHEMIA MEDICA 27 (2), p. 411 - 417.

2016

• CAPOOR, MN; RUZICKA, F; MACHACKOVA, T; JANCALEK, R; SMRCKA, M; SCHMITZ, JE; HERMANOVA, M; SANA, J; MICHU, E; BAIRD, JC; AHMED, FS; MACA, K; LIPINA, R; ALAMIN, TF; COSCIA, MF; STONEMETZ, JL; WITHAM, T; EHRLICH, GD; GOKASLAN, ZL; MAVROMMATIS, K; BIRKENMAIER, C; FISCHETTI, VA; SLABY, O, 2016:Prevalence of Propionibacterium acnes in Intervertebral Discs of Patients Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study. PLOS ONE 11 (8)
• DVORAKOVA, P; KYR, M; NEKULOVA, M; JEZOVA, M; PAVELKA, Z; SLABY, O; STERBA, J; VOJTESEK, B; HERNYCHOVA, L; ZITTERBART, K, 2016:QUANTITATIVE PROTEOMIC PROFILING IN MEDULLOBLASTOMA RECAPITULATES SUBGROUPING BASED ON TRANSCRIPTIONAL PROFILES. NEURO-ONCOLOGY 18 , p. 117 - 117.
• KLEMENT, GL; ARKUN, K; VALIK, D; ROFFIDAL, T; HASHEMI, A; KLEMENT, C; CARMASSI, P; RIETMAN, E; SLABY, O; MAZANEK, P; MUDRY, P; KOVACS, G; KISS, C; NORGA, K; KONSTANTINOV, D; ANDRE, N; SLAVC, I; VAN DEN BERG, H; KOLENOVA, A; KREN, L; TUMA, J; SKOTAKOVA, J; STERBA, J, 2016:Future paradigms for precision oncology. ONCOTARGET 7 (29), p. 46813 - 46831.
• MERHAUTOVA, J; DEMLOVA, R; SLABY, O, 2016:MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers. FRONTIERS IN PHARMACOLOGY 7
• MLCOCHOVA, H; MACHACKOVA, T; RABIEN, A; RADOVA, L; FABIAN, P; ILIEV, R; SLABA, K; POPRACH, A; KILIC, E; STANIK, M; REDOVA-LOJOVA, M; SVOBODA, M; DOLEZEL, J; VYZULA, R; JUNG, K; SLABY, O, 2016:Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. SCIENTIFIC REPORTS 6
• NEMECEK, R; BERKOVCOVA, J; SLABY, O; SVOBODA, M, 2016:Next generation sequencing mutational analysis of primary and metastatic colorectal cancer samples in relationship to efficacy of cetuximab-based therapy. ANNALS OF ONCOLOGY 27 , p. 3 - 3.
• THORENOOR, N; FALTEJSKOVA-VYCHYTILOVA, P; HOMBACH, S; MLCOCHOVA, J; KRETZ, M; SVOBODA, M; SLABY, O, 2016:Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. ONCOTARGET 7 (1), p. 622 - 637.
• VYCHYTILOVA-FALTEJSKOVA, P; RADOVA, L; SACHLOVA, M; KOSAROVA, Z; SLABA, K; FABIAN, P; GROLICH, T; PROCHAZKA, V; KALA, Z; SVOBODA, M; KISS, I; VYZULA, R; SLABY, O, 2016:Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. CARCINOGENESIS 37 (10), p. 941 - 950.

2015

• BESSE, L; SEDLARIKOVA, L; KRYUKOV, F; NEKVINDOVA, J; RADOVA, L; SLABY, O; KUGLIK, P; ALMASI, M; PENKA, M; KREJCI, M; ADAM, Z; POUR, L; SEVCIKOVA, S; HAJEK, R, 2015:Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLOS ONE 10 (9)
• MLCOCHOVA, J; FALTEJSKOVA-VYCHYTILOVA, P; FERRACIN, M; ZAGATTI, B; RADOVA, L; SVOBODA, M; NEMECEK, R; JOHN, S; KISS, I; VYZULA, R; NEGRINI, M; SLABY, O, 2015:MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. ONCOTARGET 6 (36), p. 38695 - 38704.

2014

• SANA, J; RADOVA, L; LAKOMY, R; KREN, L; FADRUS, P; SMRCKA, M; BESSE, A; NEKVINDOVA, J; HERMANOVA, M; JANCALEK, R; SVOBODA, M; HAJDUCH, M; SLAMPA, P; VYZULA, R; SLABY, O, 2014:Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. CARCINOGENESIS 35 (12), p. 2756 - 2762.